A 52-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (200 and 400 mcg o.d.) in patients with chronic obstructive pulmonary disease using formoterol (12 mcg b.i.d.) as an active control.
Phase of Trial: Phase III
Latest Information Update: 23 May 2011
At a glance
- Drugs Formoterol; Indacaterol
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Novartis
- 23 May 2011 This trial is recruiting in Great Britain and has completed in Germany and discontinued in Sweden.
- 17 May 2011 New trial record